Healthcare is undergoing a seismic shift from reactive treatment to predictive prevention and longevity. We invest in companies leveraging AI, genomics, regenerative medicine, and neurotechnology to eliminate disease, reverse aging, and extend healthy lifespans to 120+ years. Our portfolio is pioneering the biotechnology infrastructure for century-long healthspans.
AI-powered drug discovery platforms like Atomwise and Verge Genomics reduce development timelines from 15+ years to 3-5 years, accelerating breakthroughs in cancer, Alzheimer’s, and rare diseases.
100x
Faster drug discovery through AI and machine learning platforms
Companies like HexemBio and Stamm Bio are developing regenerative therapies and stem cell technologies, with clinical trials showing potential to extend healthy lifespans by 20-30 years.
ncluding Dexai Robotics, Aurora Innovation, and Athenahealth, highlighting Draper’s role in scaling breakthrough automation tech. market by 2030
Since 2015, Draper has backed genomics pioneers like Form Bio and Ten63 Therapeutics, developing personalized therapies and diagnostics that prevent disease based on individual genetic profiles.
2015
Year Draper began major investments in precision medicine and genomics
Aging is a treatable condition. Companies like HexemBio are reversing cellular aging through stem cell therapies and cellular reprogramming.
AI platforms from Atomwise and Verge Genomics analyze millions of molecular interactions, accelerating drug discovery for complex diseases like Alzheimer’s and cancer.
Form Bio and Ten63 Therapeutics develop personalized treatments using genetic and lifestyle data, preventing disease before symptoms appear.
Trestle Bio and Stamm Bio are pioneering tissue engineering and biomanufacturing, enabling organ repair and cellular rejuvenation.
Phantom Neuro and Precision Neuro are developing brain-computer interfaces to restore mobility and treat neurodegenerative diseases like Alzheimer’s.
We back companies developing longevity therapies, AI-powered diagnostics, gene editing, regenerative medicine, neurotechnology, and personalized treatments to eliminate disease and extend lifespans.
Our healthcare portfolio includes Form Bio (AI drug discovery), Ten63 Therapeutics (computational drug discovery), Verge Genomics (neurological diseases), Atomwise (AI-driven therapeutics), HexemBio (stem cell therapy), Precision Neuro (neurotechnology), Phantom Neuro (brain-computer interfaces), Stamm Bio (biomanufacturing), and Trestle Bio (implantable therapeutics). These companies are transforming healthcare.
We’re excited about longevity therapies, AI diagnostics, gene editing, regenerative medicine, neurotechnology, and preventative healthcare solutions that make century-long healthspans a reality.